Tuesday, September 8, 2009

Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist http://bit.ly/bqY3J
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)